When undergoing a prostate cancer screening, most men have to undergo a lengthy process to ensure they are given a proper diagnosis.
A new blood test for prostate cancer has shown a 99% accuracy rating. This test not only determines whether a man has prostate cancer, but it also can determine the current stage and progression of cancer.
This is the first blood test for prostate cancer to achieve such a high rating for testing validity.
New Prostate Cancer Blood Test Development
According to the American Cancer Society, there have been over 190,000 new cases of prostate cancer in 2020 alone.
While prostate cancer can be treated successfully in its early stages, current modalities make detection difficult. The standard blood markers for determining prostate cancer are unusual levels of a protein called PSA.
This can appear normal in about 15% of people who do have prostate cancer, so patients and doctors are left to believe there is nothing to worry about, meanwhile the disease progresses to get worse.
Prostate Cancer Blood Test Research
Researchers from Nottingham Trent University and University Hospitals Leicester NHS Trust were both involved in the development of this innovative new test.
The team determined that alterations in a patient’s immune system could be examined through white blood cells – these white blood cells act as blood markers.
The team then developed a series of advanced tools for analyzing blood samples to determine the presence and stage of cancer at up to 99% accuracy.
Professor Graham Pockley who is the Director of Nottingham Trent University’s John van Geest Cancer Research Center said, “Our approach not only identifies the presence of the disease but also—crucially—its clinical significance. We can also do this with higher accuracy than current approaches.”
Determining the stage and progression of prostate cancer is so crucial because this is how physicians know how much of a health risk the prostate cancer may impose.
Benefits of Prostate Cancer Blood Test
This new blood test helps reduce the need for invasive biopsies and scans.
Professor Pockley commented, “This will spare men from having unnecessary invasive procedures and help clinicians to decide whether to ‘watch’ or ‘actively manage’ patients, even when they are asymptomatic.”
The new blood test also saves patients, as well as medical practices a lot of money by omitting biopsies and scans, as well as catching cancer in an earlier stage to allow for a less expensive, minimally invasive procedure to treat the disease.
Minimally Invasive Prostate Cancer Treatment in Miami With CyberKnife
At the CyberKnife Center of Miami, we have nearly 20 years of experience in treating prostate cancer patients and helping them return to a full, active lifestyle with little to no treatment side effects.
Dr. Mark Pomper, Medical Director at CyberKnife Miami has helped thousands of patients achieve wellness.
Dr.Pomper says, “CyberKnife for prostate cancer treatment provides an amazingly precise way to deliver radiation to the diseased area. Treatment only takes about 5 sessions over about 2 weeks. CyberKnife is not available everywhere, but we are very fortunate to have a highly experienced team at our Miami office. At the CyberKnife Center of Miami, we have a 97% cure rate for prostate cancer.”
You can learn more about the successful treatment of prostate cancer with CyberKnife by visiting our website at www.prostatecancertreatmentmiami.com/.
If you’d like to make an appointment or speak to a member of our staff, you can call our office at (305) 279-2900.